MacroGenics, Inc. (MGNX) 股票分析

公司概述

MacroGenics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery, development, manufacturing, and commercialization of antibody-based therapeutics designed for cancer treatment within the United States market. The company functions within the broader healthcare sector, specifically navigating the highly competitive and capital-intensive biotechnology industry where product pipelines are critical for long-term value creation. In terms of operational scale, MacroGenics maintains a market capitalization of $218.65M, reports annual revenue of $149.50M, and employs a workforce of 293 individuals. These valuation and revenue figures indicate that the company is a mid-sized player in the biotechnology landscape, possessing sufficient cash reserves to fund its clinical-stage initiatives while maintaining a significant employee base relative to its market cap size.

财务健康

MacroGenics reported a trailing twelve-month revenue of $149.50M, yet recorded a net income loss of $-74,620,000 and an EBITDA of $-65,669,000. The substantial gap between positive revenue and significant net income losses reveals a cost structure dominated by high research and development expenses typical of clinical-stage biopharmaceutical firms, where costs often exceed immediate revenue generation. The company's free cash flow stands at $-58,232,124, which signifies a consumption of cash to fund operations and pipeline advancement, thereby limiting current financial flexibility for non-core expenditures. Profitability metrics show a gross margin of -22.5%, an operating margin of -29.3%, and a profit margin of -49.9%, all indicating that the company is currently burning cash at every level of its income statement before interest and taxes. Regarding liquidity, MacroGenics holds $189.91M in cash against $36.76M in debt, resulting in a debt-to-equity ratio of 66.13, which suggests a leveraged balance sheet relative to equity but one supported by substantial cash reserves. The current ratio is recorded at 5.10, indicating a robust ability to meet short-term obligations with current assets. Return on equity is -86.9% and return on assets is -17.6%, metrics that reflect the dilutive effect of net losses on shareholder equity and asset utilization efficiency during the growth phase of the business.

估值评估

The valuation metrics present a unique picture for a loss-making biotechnology firm, with a trailing P/E ratio of N/A and a forward P/E of -3.55. The divergence between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in potential future earnings recovery or is utilizing alternative valuation methods given the current lack of profitability. The price-to-book ratio is 3.92, indicating that the market values MacroGenics at nearly four times its net book value, suggesting a premium assigned to its intangible assets and clinical pipeline. Alternative valuation multiples include a price-to-sales ratio of 1.46 and an EV/EBITDA of -1.00, which suggest the market is valuing the company primarily on its revenue generation capacity rather than current earnings power. The stock has traded between a 52-week low of $1.02 and a 52-week high of $3.54, with the current market dynamics reflecting volatility within this specific range. The beta value is 1.10, meaning the stock's price volatility is 10% higher than the broader market index, highlighting the elevated risk profile associated with clinical-stage biotechnology investments.

Growth & Income

Revenue growth year-over-year has surged to 113.0%, demonstrating a rapid expansion in top-line sales, while earnings growth is listed as N/A due to the company's ongoing losses. The absence of positive earnings growth relative to revenue expansion is typical for early-stage biotechs, implying that top-line scaling is prioritized over immediate profitability in the current business cycle. As a non-dividend payer, MacroGenics maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company reinvests all available earnings and cash flow into research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by aggressive revenue expansion funded by significant cash reserves, with no current commitment to shareholder returns, focusing entirely on advancing its pipeline of bispecific DART molecules like lorigerlimab.